In this week’s View, Dr. Eagle explores the impact of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on the recurrence of atrial fibrillation after catheter ablation in patients with type-2 diabetes, then discusses the differences and similarities between the ACC/AHA and ESC/EACTS guidelines for the management of valvular heart diseases. Finally, Dr. Eagle looks at data from the VICTORIA Trial and asks whether age or sex affect the outcome of patients with heart failure with reduced ejection fraction. 

Subscribe to Eagle’s Eye View